Physician profile
James Christopher Beard
NPI 1053469569
$914.41
in general payments reported to CMS, 2019-2025
18 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $266.78 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $180.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $89.02 | 2019 | |
| Novo Nordisk INC | $83.57 | 2019 | |
| Shire North American Group INC | $35.21 | 2019 | |
| Ibsa Pharma INC. | $31.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.90 | 2019 | |
| Insulet Corporation | $23.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.76 | 2019 | |
| Abbvie INC. | $23.68 | 2019 | |
| Dexcom, INC. | $22.87 | 2019 | |
| Radius Health, INC. | $18.32 | 2019 | |
| Medtronic Minimed, INC. | $18.08 | 2019 | |
| Gilead Sciences, INC. | $17.83 | 2019 | |
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $11.67 | 2019 | |
| Corcept Therapeutics | $11.65 | 2019 | |
| Companion Medical, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.